03 aug: SKAGEN Fondene: Lys i mørket ?
04 aug: SORT KANT – 12 COOL DESIGNHITS
04-08-2011 07:31:01

First half of 2011: Dräger continues successful trend

Drägerwerk AG & Co. KGaA /

First half of 2011: Dräger continues successful trend

. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

  • Order intake and net sales up

  • EBIT margin amounts to 9.1 percent.

  • Equity ratio rises to 34 percent 

Lübeck - Drägerwerk AG & Co. KGaA's order intake and net sales increased in the first half of 2011. Order intake after the first six months of 2011 totaled EUR 1.11 billion, 6.3 percent (net of currency effects) higher than in the previous year (6 months 2010: EUR 1.05 billion). Order intake in the second quarter of 2011 developed very differently in the two divisions: While order intake in the safety division rose by 8.9 percent (net of currency effects), order intake in the medical division dropped by 2.3 percent (net of currency effects). A large order from Brazil had led to an extraordinarily high order basis in the previous year's period. Group sales rose by 2.3 percent (net of currency effects) to approximately EUR 1.03 billion in the first six months of 2011 (6 months 2010: EUR 1.02 billion).

 

Dräger invests in new products and markets

Dräger increased its gross profit by EUR 24.2 million against the first half of 2010 to approximately EUR 514.0 million, up 5.0 percent. This was mainly due to continuing strong demand from the high-margin business with industrial customers and the overall high level of capacity utilization in the safety division. However, functional costs rose disproportionately by around 9 percent. Dräger invested 12.3 percent more in research and development alone than in the previous year. "In 2011, we will invest more in future products and market potentials as well as in the expansion of sales activities", said Stefan Dräger, Chairman of the Executive Board of Drägerwerk Verwaltungs AG. At EUR 94.5 million, Dräger's EBIT was down 8.0 percent on the previous year in the first half of 2011 (6 months 2010: EUR 102.6 million). The EBIT margin was 9.1 percent (6 months 2010: 10.1 percent). Earnings after income taxes amounted to EUR 53.7 million, down slightly on the previous year's period (6 months 2010: EUR 55.9 million).

 

Improved equity ratio

Dräger's equity rose by EUR 4.0 million to EUR 640.6 million in the first six months of 2011. This increase was mainly the result of earnings in the first half of 2011 as well as the offsetting effects of the dividend payments and the negative differences arising from currency translations at the foreign subsidiaries. The equity ratio went up to 34.0 percent (December 31, 2010: 32.2 percent). "This performance brings us a step closer to achieving an equity ratio of at least 35 percent. This is important to counter the fluctuating global economy, as is flexibility when it comes to capacities and costs," emphasized Stefan Dräger.

 

Outlook: Forecast increased in July

On July 19, 2011, Dräger increased its forecast for the current financial year. The Company now anticipates an EBIT margin between 8.0 percent and 9.5 percent (previously: 7.5 percent to 8.5 percent) - based on the unchanged assumption of slight sales growth. Dräger anticipates that order intake will grow at least as fast as the entire global economy (IMF June 2011 forecast: +4.3 percent). Net sales growth in 2011 will be one to two percentage points down on order intake growth as net sales in 2010 benefited from above-average order intake in the fourth quarter of 2009.

 

Dräger plans to invest more in product development and the Group-wide IT infrastructure. However, the costs for the new marketing and sale structure in 2011 will not come to the same figure as originally planned.

 

The estimated development of net sales and margins is based on the assumption that the markets relevant to Dräger will continue their steady development and that exchange rates will remain unchanged. Global uncertainty factors have increased further, which makes an exact forecast difficult.

 

Key figures for the first six months of 2011 (in EUR million)

  Q2 2011 Q2 2010 H1 2011 H1 2010 Change Net of currency effects
Order intake 555.5 560.7 1,109.1 1,048.9 +5.7 % +6.3 %

Medical division

356.7

375.2

713.9

698.8

+2.2 %

+3.0 %

Safety division

206.2

192.8

410.2

365.1

+12.4 %

+12.2 %

             
Net sales 533.1 550.8 1,033.3 1,016.7 +1.6% +2.3%

Medical division

341.4

371.1

663.0

677.2

-2.1%

-1.1%

Safety division

199.2

186.0

385.2

353.0

+9.1%

+9.1%

             
EBIT[1] 51.9 65.8 94.5 102.6 -8.0%  

Medical division

39.3

52.6

69.9

93,0

-24.8%

 

Safety division

24.2

16.6

45.8

29.3

+56.5%

 

             
EBIT margin 9.7% 11.9% 9.1% 10.1%    
Earnings after income taxes 30.4 37.2  

53.7

55.9    
EPS[2] preferred shares 1.60 2.37 2.82 3.75    
EPS[2] common shares 1.59 2.36 2.79 3.72    

 

[1] EBIT = Earnings before interest and taxes

[2] EPS = Earnings per share (in €)

 

Disclaimer

This press release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

 

 

Kontakt

           

Corporate Communications:

Melanie Kamann

Tel. +49 451 882-3998

melanie.kamann@draeger.com

 

Investor Relations:

Vanina Hoffmann

Tel. +49 451 882-2685

vanina.hoffmann@draeger.com

 

 

Drägerwerk AG & Co. KGaA     

Moislinger Allee 53-55

23558 Lübeck, Germany

www.draeger.com

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

HUG#1536117

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
20 apr
PNDORA
  Jeg har flere gange analyseret Pandora, senest den 23. marts efter årsregnskabet. Den seneste tid ..
38
18 apr
PNDORA
Jeg har læse op på denne aktie i aften idet jeg ikke forstår at en C20 aktie kan få så stort et fald..
31
21 apr
PNDORA
Du er dødbringende for EI, Goodwrench. Man gider snart ikke læse med mere, når du forurener/destruer..
29
23 apr
BAVA
Tag det roligt.....Baronen er EI's største klovn og han elsker at optræde:-)
23
21 apr
PNDORA
Styr dog det der Aspergers eller ADHD du kæmper med - hvad skal vi dog med de tåbelige kommentarer f..
21
13:21
PNDORA
Her er de aktier der har min opmærksomhed... Bemærk en gang iskoldt overblik og common sense er i sp..
20
20 apr
 
EU skal tilbage til en handels afale landene imellem, glem alt omfaelles regering,faelles valuta og ..
18
19 apr
VWS
Man er nødt til at erkende ganske få ting for at forstå Vestas....   Gennem tiden har Vestas haft el..
18
24 apr
BAVA
  Tirsdag 25/4 generalforsamling Torsdag den 4/5 Q1 regnskab   Vi har den 1/5 om fire børsdage, ge..
17
23 apr
PNDORA
  Det meste tyder i mine øjne på, at Pandora showet fortsætter næste uge med nye fald.       Jeg ove..
17

Vestas vil til tops i Indien - citat

25-04-2017 15:02:38
Tirsdag blev Vestas' seneste 2 megawatts-vindmølle lanceret i New Delhi, og Clive Turton, der er chef for Vestas' Asien-afdeling slog fast, at den danske vindmølleproducent vil være førende i Indien.- Inden er det mest vigtige og afgørende marked i Asien-Stillehavet-regionen. Vi mener, vi har den bedste teknologi, og nu kan Vestas komme på førstepladsen her i landet, sagde Clive Turton til branche..

Novo: Amerikansk rival har stærkt diabetessalg i første kvartal

25-04-2017 12:33:38
En af Novo Nordisks største konkurrenter - det amerikanske medicinalselskab Eli Lilly - solgte mere diabetesmedicin i første kvartal end ventet af analytikerne. Også indtjeningen overrasker til den positive side.Eli Lilly kom ud af kvartalet med et nettooverskud på 1040 mio. dollar mod 882 mio. dollar i samme periode sidste år. Det justerede resultat per aktie landede på 0,98 dollar, hvilket var e..

Aktier/åbning: C20 Cap fortsætter kursen mod rekord

25-04-2017 09:26:57
Der er tirsdag morgen stadig en smule brændstof tilbage i det franske valgresultat til nye stigninger på aktiemarkederne.Ingen af de danske eliteaktier gør dog særligt væsen af sig, og man skal ud blandt sidepapirerne for at finde større bevægelser til blandt andet FLSmidth og Össur. FLS-aktien stiger efter godt nyt fra en konkurrent, mens Össur er i modvind oven på en sænket anbefaling fra Nordea..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas-rival risikerer farvel til børsen efter nyt milliardunderskud
2
Aktier/tendens: Bankerne i fokus på ny plusdag
3
Genmabs Arzerra-partner rammer over forventningerne
4
Novo: Amerikansk rival har stærkt diabetessalg i første kvartal
5
Skat må formentlig vinke farvel til 80 milliarder kroner

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. april 2017 18:23:21
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170403.1 - EUROWEB3 - 2017-04-25 18:23:21 - 2017-04-25 18:23:21 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x